Didier A Mandelbrot

List of Publications by Year
in descending order

208 papers	4,685 citations	126907 33 h-index	133252 59 g-index
208 all docs	208 docs citations	208 times ranked	5188 citing authors

#	Article	IF	Citations
1	Motivations and outcomes of compatible living donorâ€"recipient pairs in paired exchange. American Journal of Transplantation, 2022, 22, 266-273.	4.7	13
2	Letermovir conversion after valganciclovir treatment in cytomegalovirus highâ€risk abdominal solid organ transplant recipients may promote development of cytomegalovirusâ€specific cell mediated immunity. Transplant Infectious Disease, 2022, 24, e13766.	1.7	12
3	Risk factors and outcomes of BK viremia among deceased donor kidney transplant recipients based on donor characteristics. Transplant Infectious Disease, 2022, 24, e13768.	1.7	3
4	Factors affecting sensitization following kidney allograft failure. Clinical Transplantation, 2022, 36, e14558.	1.6	3
5	Understanding and Overcoming Financial Risks for Living Organ Donors. American Journal of Kidney Diseases, 2022, 79, 159-161.	1.9	5
6	Utility of Protocol Pancreas Biopsies for De Novo Donor-specific Antibodies. Transplantation Direct, 2022, 8, e1287.	1.6	2
7	How Should Acute T-cell Mediated Rejection of Kidney Transplants Be Treated: Importance of Follow-up Biopsy. Transplantation Direct, 2022, 8, e1305.	1.6	5
8	Transplant Recipient Experience With Belatacept Therapy. Transplantation Proceedings, 2022, 54, 1604-1608.	0.6	1
9	The Presence of Donor-specific Antibodies Around the Time of Pancreas Graft Biopsy With Rejection Is Associated With an Increased Risk of Graft Failure. Transplantation, 2022, 106, e289-e296.	1.0	3
10	Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard. Transplant Infectious Disease, 2022, 24, .	1.7	16
11	Kidney delayed graft function after combined kidney-solid organ transplantation: A review. Transplantation Reviews, 2022, 36, 100707.	2.9	4
12	In kidney recipients from the same deceased donor, discordance in delayed graft function is associated with the worst outcomes. Clinical Transplantation, 2022, 36, .	1.6	5
13	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 475-483.	4.7	45
14	Kidney transplantation for primary glomerulonephritis: Recurrence risk and graft outcomes with related versus unrelated donors. Transplantation Reviews, 2021, 35, 100584.	2.9	0
15	Incidence, risk factors, and outcomes of postâ€transplant erythrocytosis after kidney transplantation. Clinical Transplantation, 2021, 35, e14166.	1.6	7
16	Single center results of simultaneous pancreas-kidney transplantation in patients with type 2 diabetes. American Journal of Transplantation, 2021, 21, 2810-2823.	4.7	17
17	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	4.7	67
18	Risk factors for progression from low level BK dnaemia to unfavorable outcomes after BK management via immunosuppressive reduction. Transplant Infectious Disease, 2021, 23, e13561.	1.7	5

#	Article	IF	Citations
19	Impact and outcomes of primary cytomegalovirus disease in seronegative abdominal solid organ transplant recipients of cytomegalovirus unexposed donors (Dâ€Râ€). Transplant Infectious Disease, 2021, 23, e13564.	1.7	3
20	Living Related Donor Kidney Transplantation in Atypical HUS: When Should It Be Considered?. Kidney360, 2021, 2, 524-527.	2.1	1
21	Risk factors and outcomes for delayed kidney graft function in simultaneous heart and kidney transplant recipients: A UNOS/OPTN database analysis. American Journal of Transplantation, 2021, 21, 3005-3013.	4.7	5
22	Wages, Travel, and Lodging Reimbursement by the National Kidney Registry: An Important Step Toward Financial Neutrality for Living Kidney Donors in the United States. Transplantation, 2021, 105, 2606-2611.	1.0	12
23	Graft Function Variability and Slope and Kidney Transplantation Outcomes. Kidney International Reports, 2021, 6, 1642-1652.	0.8	2
24	Cytomegalovirus antiviral stewardship in the COVIDâ€19 Era: Increasing complexity of prophylaxis and treatment and potential mitigation strategies. Transplant Infectious Disease, 2021, 23, e13586.	1.7	9
25	Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation. Transplant Infectious Disease, 2021, 23, e13617.	1.7	5
26	Sodium zirconium cyclosilicate use in kidney transplant recipients. Nephrology Dialysis Transplantation, 2021, 36, 2151-2153.	0.7	2
27	Continuation of Peritoneal Dialysis in Adult Kidney Transplant Recipients With Delayed Graft Function. Kidney International Reports, 2021, 6, 1634-1641.	0.8	6
28	Successful management of Tâ€cell mediated rejection in a recent kidney transplant recipient with COVIDâ€19 associated severe acute respiratory syndrome. Transplant Infectious Disease, 2021, 23, e13598.	1.7	7
29	Bimonthly viral monitoring for lateâ€onset cytomegalovirus infectionâ€"Balancing efficacy with patient palatability; A reply to Melgarejo et al. Clinical Transplantation, 2021, 35, e14348.	1.6	2
30	Geographic Distribution of Cytomegalovirus Serology in Kidney and Pancreas Transplant Recipients in the United States. Transplantation Direct, 2021, 7, e704.	1.6	6
31	Modest Improvements in Refractory Antibody-Mediated Rejection After Prolonged Treatment. Kidney International Reports, 2021, 6, 1397-1401.	0.8	1
32	Outcomes of Delayed Graft Function in Kidney Transplant Recipients Stratified by Histologic Biopsy Findings. Transplantation Proceedings, 2021, 53, 1462-1469.	0.6	10
33	Frailty in Pancreas Transplantation. Transplantation, 2021, 105, 1685-1694.	1.0	3
34	Postâ€kidney transplant serum magnesium exhibits a Uâ€shaped association with subsequent mortality: an observational cohort study. Transplant International, 2021, 34, 1853-1861.	1.6	4
35	Discrepant subtyping of blood type A2 living kidney donors: Missed opportunities in kidney transplantation. Clinical Transplantation, 2021, 35, e14422.	1.6	3
36	Transplant kidney biopsy for proteinuria with stable creatinine: Findings and outcomes. Clinical Transplantation, 2021, 35, e14436.	1.6	6

#	Article	IF	Citations
37	The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients. Transplant Infectious Disease, 2021, 23, e13693.	1.7	13
38	The Evaluation of Kidney Function in Living Kidney Donor Candidates. Kidney360, 2021, 2, 1523-1530.	2.1	12
39	A pilot study of an intensified ganciclovir dosing strategy for treatment of cytomegalovirus disease in kidney and/or pancreas transplant recipients. Clinical Transplantation, 2021, 35, e14427.	1.6	3
40	Preâ€transplant bariatric surgery is not associated with an increased risk of infection after kidney transplant. Transplant International, 2021, 34, 1989-1991.	1.6	2
41	Impact of lowâ€level pretransplant donorâ€specific antibodies on outcomes after kidney transplantation. Immunity, Inflammation and Disease, 2021, 9, 1508-1519.	2.7	4
42	Cytomegalovirus nephritis in kidney transplant recipients: Epidemiology and outcomes of an uncommon diagnosis. Transplant Infectious Disease, 2021, 23, e13702.	1.7	5
43	Transplant Options for Patients With Diabetes and Advanced Kidney Disease: A Review. American Journal of Kidney Diseases, 2021, 78, 418-428.	1.9	17
44	Significance of Asymptomatic Pyelonephritis Found on Kidney Transplant Biopsy. Transplantation Direct, 2021, 7, e764.	1.6	1
45	The clinical value of donor-derived cell-free DNA measurements in kidney transplantation. Transplantation Reviews, 2021, 35, 100649.	2.9	9
46	Factors Associated With Residual Kidney Function and Proteinuria After Living Kidney Donation in the United States. Transplantation, 2021, 105, 372-381.	1.0	5
47	The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies. Transplantation, 2021, 105, 1548-1555.	1.0	8
48	Association of Human Leukocyte Antigen Mismatches Between Donorâ€recipient And Donorâ€donor in Pancreas after Kidney Transplant Recipients. Transplant International, 2021, , .	1.6	3
49	Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease. Kidney360, 2021, 2, 312-324.	2.1	6
50	Treatment of Chronic Active Antibody-mediated Rejection With Pulse Steroids, IVIG, With or Without Rituximab is Associated With Increased Risk of Pneumonia. Transplantation Direct, 2021, 7, e644.	1.6	3
51	P.131: Persistent Low Blood Pressure After Simultaneous Pancreas and Kidney Transplant Is not Associated With an Increased Risk of Allograft Loss. Transplantation, 2021, 105, S51-S51.	1.0	0
52	406.4: Induction in Pancreas Transplantation: T-cell Depletion vs. IL-2 Receptor Blockade. Transplantation, 2021, 105, S32-S32.	1.0	0
53	New Approaches to Cardiovascular Disease and its Management in Kidney Transplant Recipients. Transplantation, 2021, Publish Ahead of Print, .	1.0	3
54	Kidney transplant outcomes among recipients with postâ€transplant hip or knee joint replacement surgery. Clinical Transplantation, 2021, , e14564.	1.6	2

#	Article	IF	Citations
55	Living donor program crisis management plans: Current landscape and talking point recommendations. American Journal of Transplantation, 2020, 20, 546-552.	4.7	9
56	Patterns and predictors of fatigue following living donor nephrectomy: Findings from the KDOC Study. American Journal of Transplantation, 2020, 20, 181-189.	4.7	13
57	Performance of Creatinine Clearance and Estimated GFR in Assessing Kidney Function in Living Donor Candidates. Transplantation, 2020, 104, 575-582.	1.0	9
58	More Than 25 Years of Pancreas Graft Survival After Simultaneous Pancreas and Kidney Transplantation: Experience From the World's Largest Series of Long-term Survivors. Transplantation, 2020, 104, 1287-1293.	1.0	12
59	Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients. Kidney360, 2020, 1, 1407-1418.	2.1	4
60	Characteristics and Graft Survival of Kidney Transplant Recipients with Renal Cell Carcinoma. American Journal of Nephrology, 2020, 51, 777-785.	3.1	3
61	A Single-Center Assessment of Delayed Graft Function in Recipients of Simultaneous Liver and Kidney Transplant. Progress in Transplantation, 2020, 30, 342-348.	0.7	3
62	Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Injury in Kidney Transplant Recipients During the Time of the Coronavirus Disease 2019 Pandemic. Transplantation Proceedings, 2020, 52, 2592-2595.	0.6	6
63	The care of kidney transplant recipients during a global pandemic: Challenges and strategies for success. Transplantation Reviews, 2020, 34, 100567.	2.9	9
64	Alloimmunity in pancreas transplantation. Current Opinion in Organ Transplantation, 2020, 25, 322-328.	1.6	9
65	Serum Albumin Level Before Kidney Transplant Predicts Post-transplant BK and Possibly Cytomegalovirus Infection. Kidney International Reports, 2020, 5, 2228-2237.	0.8	10
66	Early Report on Published Outcomes in Kidney Transplant Recipients Compared to Nontransplant Patients Infected With Coronavirus Disease 2019. Transplantation Proceedings, 2020, 52, 2659-2662.	0.6	21
67	Donor-specific antibodies in kidney transplantation: the University of Wisconsin experience. Current Opinion in Organ Transplantation, 2020, 25, 543-548.	1.6	2
68	Editorial: The cutting edge of donor-specific antibodies in transplantation. Current Opinion in Organ Transplantation, 2020, 25, 527-528.	1.6	0
69	Care of international living kidney donor candidates in the United States: A survey of contemporary experience, practice, and challenges. Clinical Transplantation, 2020, 34, e14064.	1.6	10
70	Obesity: An Independent Predictor of Morbidity and Graft Loss after Kidney Transplantation. American Journal of Nephrology, 2020, 51, 615-623.	3.1	14
71	Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era. Kidney International Reports, 2020, 5, 1894-1905.	0.8	54
72	The kidney evaluation of living kidney donor candidates: US practices in 2017. American Journal of Transplantation, 2020, 20, 3379-3389.	4.7	29

#	Article	IF	Citations
73	Metabolic, cardiovascular, and substance use evaluation of living kidney donor candidates: US practices in 2017. American Journal of Transplantation, 2020, 20, 3390-3400.	4.7	21
74	Epidemiology, management, and graft outcomes after West Nile virus encephalitis in kidney transplant recipients. Transplant Infectious Disease, 2020, 22, e13317.	1.7	9
75	Third-party vessel allografts in kidney and pancreas transplantation: Utilization, de novo DSAs, and outcomes. American Journal of Transplantation, 2020, 20, 3443-3450.	4.7	3
76	Prediction of cytomegalovirus infection: A singleâ€center experience utilizing a newly available cellâ€mediated immunity assay by flow cytometry, a risk factor screening tool, and serologically demonstrated immunity. Transplant Infectious Disease, 2020, 22, e13311.	1.7	10
77	The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients. Infection Control and Hospital Epidemiology, 2020, 41, 1068-1074.	1.8	21
78	Outcomes of simultaneous pancreas and kidney transplants based on preemptive transplant compared to those who were on dialysis before transplant â€" a retrospective study. Transplant International, 2020, 33, 1106-1115.	1.6	8
79	Prevalence of primary aldosteronism in hypertensive kidney transplant recipients: A crossâ€sectional study. Clinical Transplantation, 2020, 34, e13999.	1.6	4
80	Pain expectancy, prevalence, severity, and patterns following donor nephrectomy: Findings from the KDOC Study. American Journal of Transplantation, 2020, 20, 2522-2529.	4.7	10
81	Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients. Transplantation Direct, 2020, 6, e526.	1.6	0
82	Incidence and Outcomes of Significant Weight Changes After Pancreas Transplant Alone. Transplantation Direct, 2020, 6, e539.	1.6	3
83	Polyomavirus and cytomegalovirus infections are risk factors for grafts loss in simultaneous pancreas and kidney transplant. Transplant Infectious Disease, 2020, 22, e13272.	1.7	6
84	Unusually high rates of acute rejection during the COVID-19 pandemic: cause for concern?. Kidney International, 2020, 98, 513-514.	5.2	20
85	One more time, emphasizing the advantage of simultaneous pancreas and kidney transplantation for patients with type 1 diabetes and endâ€stage renal disease. Transplant International, 2020, 33, 1384-1386.	1.6	4
86	Evaluation and care of international living kidney donor candidates: Strategies for addressing common considerations and challenges. Clinical Transplantation, 2020, 34, e13792.	1.6	8
87	Management of BK viremia is associated with a lower risk of subsequent cytomegalovirus infection in kidney transplant recipients. Clinical Transplantation, 2020, 34, e13798.	1.6	10
88	Delayed kidney graft function in simultaneous pancreas-kidney transplant recipients is associated with early pancreas allograft failure. American Journal of Transplantation, 2020, 20, 2822-2831.	4.7	8
89	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. American Journal of Kidney Diseases, 2020, 75, 299-316.	1.9	38
90	Short-Term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection. Kidney360, 2020, 1, 389-398.	2.1	5

#	Article	IF	Citations
91	Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction. Clinical Nephrology, 2020, 93, 77-84.	0.7	6
92	Non-obstructive coronary angiogram findings prior to kidney transplantation do not predict post-transplant cardiac events. Clinical Nephrology, 2020, 94, 273-280.	0.7	4
93	Role of novel biomarkers in kidney transplantation. World Journal of Transplantation, 2020, 10, 230-255.	1.6	26
94	Pre-transplant AT1R antibodies and long-term outcomes in kidney transplant recipients with a functioning graft for more than 5 years. Clinical Nephrology, 2020, 94, 245-251.	0.7	2
95	Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation. Clinical Transplantation, 2019, 33, e13452.	1.6	1
96	Outcomes after simultaneous kidneyâ€pancreas versus pancreas after kidney transplantation in the current era. Clinical Transplantation, 2019, 33, e13732.	1.6	17
97	Association of diagnosed obstructive sleep apnea with kidney transplant outcomes. Clinical Transplantation, 2019, 33, .	1.6	6
98	The association of acute rejection vs recurrent glomerular disease with graft outcomes after kidney transplantation. Clinical Transplantation, 2019, 33, e13738.	1.6	3
99	Nocardia infection in kidney transplant recipients: A singleâ€center experience. Transplant Infectious Disease, 2019, 21, e13192.	1.7	8
100	The risk of cytomegalovirus infection after treatment of acute rejection in renal transplant recipients. Clinical Transplantation, 2019, 33, e13636.	1.6	13
101	Donor-Specific Antibodies in the Absence ofÂRejection Are Not a Risk Factor for Allograft Failure. Kidney International Reports, 2019, 4, 1057-1065.	0.8	29
102	Clinical Significance of Microvascular Inflammation in the Absence of Anti-HLA DSA in Kidney Transplantation. Transplantation, 2019, 103, 1468-1476.	1.0	29
103	Risk of opportunistic infection in kidney transplant recipients with cytomegalovirus infection and associated outcomes. Transplant Infectious Disease, 2019, 21, e13080.	1.7	17
104	Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes. Transplantation, 2019, 103, 1722-1729.	1.0	76
105	The Association of 25-Hydroxyvitamin D Levels with Late Cytomegalovirus Infection in Kidney Transplant Recipients: the Wisconsin Allograft Recipient Database. Transplantation, 2019, 103, 1683-1688.	1.0	7
106	Harald C. Ott: Clinician-scientist, Cardiothoracic Surgeon, Massachusetts General Hospital, Harvard Medical School. Transplantation, 2019, 103, 862-863.	1.0	24
107	Pancreas Retransplant After Pancreas Graft Failure in Simultaneous Pancreas-kidney Transplants Is Associated With Better Kidney Graft Survival. Transplantation Direct, 2019, 5, e473.	1.6	7
108	Hospitalization Trends for Acute Kidney Injury in Kidney Transplant Recipients in the United States, 2004â€“2014. Transplantation, 2019, 103, 2405-2412.	1.0	5

#	Article	IF	Citations
109	How Should Pancreas Transplant Rejection Be Treated?. Transplantation, 2019, 103, 1928-1934.	1.0	17
110	Rates of Living Kidney Donor Follow-up: Findings From the KDOC Study. Transplantation, 2019, 103, e209-e210.	1.0	2
111	Management of Tumor Necrosis Factor Î± Inhibitor Therapy After Renal Transplantation: A Comparative Analysis and Associated Outcomes. Annals of Pharmacotherapy, 2019, 53, 268-275.	1.9	10
112	Sleep disorders: Serious threats among kidney transplant recipients. Transplantation Reviews, 2019, 33, 9-16.	2.9	14
113	Metabolic Acidosis 1 Year Following Kidney Transplantation and Subsequent Cardiovascular Events and Mortality: An Observational Cohort Study. American Journal of Kidney Diseases, 2019, 73, 476-485.	1.9	26
114	Histopathological characteristics and causes of kidney graft failure in the current era of immunosuppression. World Journal of Transplantation, 2019, 9, 123-133.	1.6	27
115	Risk factors for graft loss in kidney transplant recipients with g3 glomerulitis: A single-center experience. Clinical Nephrology, 2019, 91, 95-100.	0.7	2
116	Demonstration of Resistant or Wild-Type Virus in Recurrent Viremia After Ganciclovir-Resistant Cytomegaloviral Infection. Annals of Pharmacotherapy, 2018, 52, 650-654.	1.9	1
117	The Living Donor Lost Wages Trial: Study Rationale and Protocol. Current Transplantation Reports, 2018, 5, 45-54.	2.0	7
118	Which is more nephrotoxic for kidney transplants: <scp>BK</scp> nephropathy or rejection?. Clinical Transplantation, 2018, 32, e13216.	1.6	22
119	Concurrent biopsies of both grafts in recipients of simultaneous pancreas and kidney demonstrate high rates of discordance for rejection as well as discordance in type of rejection - a retrospective study. Transplant International, 2018, 31, 32-37.	1.6	27
120	Seasonality of mortality and graft failure among kidney transplant recipients in the US - a retrospective study. Transplant International, 2018, 31, 293-301.	1.6	8
121	Addressing Disparities in Living Donor Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1909-1911.	4.5	27
122	Pneumocystis jiroveci pneumonia in kidney and simultaneous pancreas kidney transplant recipients in the present era of routine post-transplant prophylaxis: risk factors and outcomes. BMC Nephrology, 2018, 19, 332.	1.8	15
123	Impact of Highâ€Dose Acyclovir Cytomegalovirus Prophylaxis Failure in Abdominal Solid Organ Transplant Recipients. Pharmacotherapy, 2018, 38, 694-700.	2.6	9
124	The feared five fungal infections in kidney transplant recipients: A singleâ€center 20â€year experience. Clinical Transplantation, 2018, 32, e13289.	1.6	15
125	<scp>BK</scp> viremia is not associated with adverse outcomes in the absence of <scp>BK</scp> nephropathy. Clinical Transplantation, 2018, 32, e13283.	1.6	10
126	Hypertension guidelines: How do they apply to kidney transplant recipients. Transplantation Reviews, 2018, 32, 225-233.	2.9	19

#	Article	IF	Citations
127	Characteristics and Outcomes of Kidney Transplant Recipients with a Functioning Graft for More than 25 Years. Kidney Diseases (Basel, Switzerland), 2018, 4, 255-261.	2.5	14
128	The Living Donor Lost Wages Trial: Study Rationale and Protocol. Current Transplantation Reports, 2018, 5, 45-54.	2.0	2
129	Barriers to the use of a federal travel grant by living kidney donors. Clinical Transplantation, 2017, 31, e12876.	1.6	8
130	Life with One Kidney: Primary Care and the Living Kidney Donor. American Journal of Medicine, 2017, 130, 763-765.	1.5	1
131	Outcomes in the highest panel reactive antibody recipients of deceased donor kidneys under the new kidney allocation system. Clinical Transplantation, 2017, 31, e12895.	1.6	10
132	Ganciclovirâ€Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature. Pharmacotherapy, 2017, 37, 1258-1271.	2.6	27
133	Predictors and Moderators of Educational Interventions to Increase the Likelihood of Potential Living Donors for Black Patients Awaiting Kidney Transplantation. Journal of Racial and Ethnic Health Disparities, 2017, 4, 837-845.	3.2	14
134	Incidence and Indications for Late Allograft Pancreatectomy While on Continued Immunosuppression. Transplantation, 2017, 101, 2228-2234.	1.0	10
135	Utility of protocol kidney biopsies for de novo donor-specific antibodies. American Journal of Transplantation, 2017, 17, 3210-3218.	4.7	40
136	Practices in the evaluation of potential kidney transplant recipients who are elderly: A survey of U.S. transplant centers. Clinical Transplantation, 2017, 31, e13088.	1.6	19
137	Moving from Intuition to Data: Building the Evidence to Support and Increase Living Donor Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1383-1385.	4.5	14
138	Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation. Transplantation Direct, 2017, 3, e227.	1.6	34
139	Kidney Transplant Recipients With Primary Membranous Glomerulonephritis Have a Higher Risk of Acute Rejection Compared With Other Primary Glomerulonephritides. Transplantation Direct, 2017, 3, e223.	1.6	6
140	Pre-transplant immune factors may be associated with BK polyomavirus reactivation in kidney transplant recipients. PLoS ONE, 2017, 12, e0177339.	2.5	12
141	A single center kidney transplant experience among ten Caucasian females with end-stage renal disease due to scleroderma. Clinical Nephrology, 2017, 88, 40-44.	0.7	1
142	The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients. Nephrology Dialysis Transplantation, 2016, 31, 1746-1753.	0.7	63
143	In Kidney Transplant Recipients With a Positive Virtual Crossmatch, High PRA was Associated With Lower Incidence of Viral Infections. Transplantation, 2016, 100, 655-661.	1.0	12
144	Concern for Lost Income Following Donation Deters Some Patients From Talking to Potential Living Donors. Progress in Transplantation, 2016, 26, 292-298.	0.7	17

#	Article	IF	Citations
145	Nature, timing, and severity of complications from ultrasound-guided percutaneous renal transplant biopsy. Transplant International, 2016, 29, 167-172.	1.6	68
146	Current outcomes of chronic active antibody mediated rejection â€“ A large single center retrospective review using the updated BANFF 2013 criteria. Human Immunology, 2016, 77, 346-352.	2.4	70
147	To tell or not to tell: attitudes of transplant surgeons and transplant nephrologists regarding the disclosure of recipient information to living kidney donors. Clinical Transplantation, 2015, 29, 1203-1212.	1.6	4
148	Renal Function and Transplantation in Liver Disease. Transplantation, 2015, 99, 1756-1764.	1.0	31
149	Evaluation of high-risk living kidney donors. Frontiers in Bioscience - Elite, 2015, 7, 181-192.	1.8	1
150	Living Donor Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1687-1695.	4.5	101
151	Patient-Reported Outcomes Following Living Kidney Donation: A Single Center Experience. Journal of Clinical Psychology in Medical Settings, 2015, 22, 160-168.	1.4	26
152	Concerns of <scp>ABO</scp> incompatible and crossmatchâ€positive potential donors and recipients about participating in kidney exchanges. Clinical Transplantation, 2015, 29, 233-241.	1.6	7
153	Disclosing Health and Health Behavior Information between Living Donors and Their Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1609-1616.	4.5	9
154	Longâ€term evaluation of analytical methods used in sirolimus therapeutic drug monitoring. Clinical Transplantation, 2014, 28, 243-251.	1.6	14
155	Development and validation of a questionnaire to assess fear of kidney failure following living donation. Transplant International, 2014, 27, 570-575.	1.6	13
156	Making House Calls Increases Living Donor Inquiries and Evaluations for Blacks on the Kidney Transplant Waiting List. Transplantation, 2014, 98, 979-986.	1.0	101
157	Hospitalizations Following Living Donor Nephrectomy in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 355-365.	4.5	29
158	Kidney Donation and Risk of ESRD. JAMA - Journal of the American Medical Association, 2014, 312, 92.	7.4	5
159	The Outcomes of Living Kidney Donation from Medically Complex Donors: Implications for the Donor and the Recipient. Current Transplantation Reports, 2014, 1, 1-9.	2.0	17
160	Efficacy of Levofloxacin in the Treatment of BK Viremia. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 583-589.	4.5	79
161	Readiness of Wait-Listed Black Patients to Pursue Live Donor Kidney Transplant. Progress in Transplantation, 2014, 24, 355-361.	0.7	21
162	Trajectories of Perceived Benefits in Living Kidney Donors. Transplantation, 2014, 97, 762-768.	1.0	19

#	Article	IF	Citations
163	A Simultaneous Liver-Kidney Transplant Recipient With IgA Nephropathy Limited to Native Kidneys and BK Virus Nephropathy Limited to the Transplant Kidney. American Journal of Kidney Diseases, 2013, 62, 331-334.	1.9	3
164	Renal Transplantation in the Setting of Early Steroid Withdrawal: A Comparison of Rabbit Antithymocyte Globulin Induction Dosing in Two Eras. American Journal of Nephrology, 2013, 38, 397-404.	3.1	5
165	Comorbidity Burden and Perioperative Complications for Living Kidney Donors in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1773-1782.	4.5	88
166	Immunosuppression after renal allograft failure: a survey of <scp>US</scp> practices. Clinical Transplantation, 2013, 27, 895-900.	1.6	29
167	Willingness to Pursue Live-Donor Kidney Transplantation Among Waitlisted Patients Infected With Human Immunodeficiency Virus (HIV). Transplantation, 2013, 95, 787-790.	1.0	6
168	The Living Kidney Donor Evaluation. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 366-371.	4.5	29
169	Evaluation of Native Kidney Recovery After Simultaneous Liver-Kidney Transplantation. Transplantation, 2012, 93, 530-535.	1.0	27
170	Living Donor Practices in the United States. Advances in Chronic Kidney Disease, 2012, 19, 212-219.	1.4	51
171	Liver transplant center risk tolerance. Clinical Transplantation, 2012, 26, E269-76.	1.6	4
172	Evaluation of relative renal function for patients who had undergone simultaneous liverâ€"kidney transplants using Tc-99m-MAG3 scintigraphy with attenuation correction from anatomical images and SPECT/CT. Nuclear Medicine Communications, 2011, 32, 738-744.	1.1	15
173	A cross-sectional study of fatigue and sleep quality before and after kidney transplantation. Clinical Transplantation, 2011, 25, E13-E21.	1.6	50
174	2011 Recommendations for the Diagnosis and Management of Gout and Hyperuricemia. Postgraduate Medicine, 2011, 123, 3-36.	2.0	92
175	A psychological intervention to improve quality of life and reduce psychological distress in adults awaiting kidney transplantation. Nephrology Dialysis Transplantation, 2011, 26, 709-715.	0.7	120
176	The Evolving Role of mTOR Inhibition in Transplantation Tolerance. Journal of the American Society of Nephrology: JASN, 2011, 22, 408-415.	6.1	60
177	Renal Allograft Failure Predictors After PAK Transplantation: Results From the New England Collaborative Association of Pancreas Programs. Transplantation, 2010, 89, 1347-1353.	1.0	21
178	mTOR inhibition: the learning curve in kidney transplantation. Transplant International, 2010, 23, 447-460.	1.6	28
179	Spouse caregivers of kidney transplant patients: quality of life and psychosocial outcomes. Progress in Transplantation, 2010, 20, 335-343.	0.7	25
180	Antiâ€"IL-2 Receptor Antibodies versus Anti-Thymocyte Globulin for Induction Therapy in Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2009, 20, 1170-1171.	6.1	6

#	Article	IF	Citations
181	Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients. Clinical Transplantation, 2009, 23, 887-896.	1.6	30
182	Outcomes With Conversion From Calcineurin Inhibitors to Sirolimus After Renal Transplantation in the Context of Steroid Withdrawal or Steroid Continuation. Transplantation, 2009, 88, 684-692.	1.0	10
183	Practices and Barriers in Long-Term Living Kidney Donor Follow-Up: A Survey of U.S. Transplant Centers. Transplantation, 2009, 88, 855-860.	1.0	65
184	Spotting the owl: surreptitious cytomegalovirus disease in a renal transplant recipient. Clinical Transplantation, 2008, 22, 391-395.	1.6	3
185	Webâ€based requests for living organ donors: who are the solicitors?. Clinical Transplantation, 2008, 22, 749-753.	1.6	15
186	Do We Know Enough to Mandate Donor Evaluation Testing?. American Journal of Transplantation, 2008, 8, 466-466.	4.7	1
187	Resolution of SLE-related soft-tissue calcification following haematopoietic stem cell transplantation. Nephrology Dialysis Transplantation, 2008, 23, 2679-2684.	0.7	21
188	Measuring the Expectations of Kidney Donors: Initial Psychometric Properties of the Living Donation Expectancies Questionnaire. Transplantation, 2008, 85, 1230-1234.	1.0	20
189	Donor Postextubation Hypotension and Age Correlate With Outcome After Donation After Cardiac Death Transplantation. Transplantation, 2008, 85, 1588-1594.	1.0	73
190	Blockade of CTLA-4 on CD4+CD25+ Regulatory T Cells Abrogates Their Function In Vivo. Journal of Immunology, 2006, 177, 4376-4383.	0.8	368
191	CD70 Signaling Is Critical for CD28-Independent CD8+T Cell-Mediated Alloimmune Responses In Vivo. Journal of Immunology, 2005, 174, 1357-1364.	0.8	88
192	Mechanism of Action of Donor-Specific Transfusion in Inducing Tolerance: Role of Donor MHC Molecules, Donor Co-stimulatory Molecules, and Indirect Antigen Presentation. Journal of the American Society of Nephrology: JASN, 2004, 15, 2423-2428.	6.1	40
193	Analysis of costimulation by 4-1BBL, CD40L, and B7 in graft rejection by gene expression profiles. Journal of Molecular Medicine, 2003, 81, 655-663.	3.9	6
194	Neutron-activation analysis: A novel method for the assay of iohexol. Translational Research, 2003, 141, 106-109.	2.3	7
195	Cutting Edge: Transplantation Tolerance through Enhanced CTLA-4 Expression. Journal of Immunology, 2003, 171, 5673-5677.	0.8	71
196	Role of novel T-cell costimulatory pathways in transplantation. Current Opinion in Organ Transplantation, 2003, 8, 25-33.	1.6	0
197	Cutting Edge: CTLA-4 (CD152) Differentially Regulates Mitogen-Activated Protein Kinases (Extracellular) Tj ETQq1 1 0.784314 rgBT /Ove Mice. Journal of Immunology, 2002, 169, 3475-3479.	0.8	68
198	Immunosuppression and BKV Nephropathy. New England Journal of Medicine, 2002, 347, 2079-2080.	27.0	30

#	Article	IF	Citations
199	CTLA-4 regulates cell cycle progression during a primary immune response. European Journal of Immunology, 2002, 32, 366-373.	2.9	115
200	Rejection of Mouse Cardiac Allografts by Costimulation in trans. Journal of Immunology, 2001, 167, 1174-1178.	0.8	42
201	CD28-independent Costimulation of T Cells in Alloimmune Responses. Journal of Immunology, 2001, 167, 140-146.	0.8	109
202	B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. Journal of Clinical Investigation, 2001, 107, 881-887.	8.2	76
203	Molecular Basis for Leukocyte Integrin Î±EÎ²7 Adhesion to Epithelial (E)-Cadherin. Journal of Experimental Medicine, 2000, 191, 1555-1567.	8.5	56
204	Association of B7-1 Co-Stimulation with the Development of Graft Arterial Disease. American Journal of Pathology, 2000, 157, 473-484.	3.8	40
205	B7-1 or B7-2 Is Required to Produce the Lymphoproliferative Phenotype in Mice Lacking Cytotoxic T Lymphocyteâ€“associated Antigen 4 (CTLA-4). Journal of Experimental Medicine, 1999, 189, 435-440.	8.5	137
206	CTLA-4 and T cell activation. Current Opinion in Immunology, 1999, 11, 294-300.	5.5	183
207	Distinct structural and functional epitopes of the Î±EÎ²7 integrin. European Journal of Immunology, 1994, 24, 2832-2841.	2.9	72
208	Identification and Characterization of a Polypeptide from a Lobster Neurosecretory Gland that Induces Cyclic GMP Accumulation in Lobster Neuromuscular Preparations. Journal of Neurochemistry, 1987, 48, 954-966.	3.9	22